Literature DB >> 15056211

Herpes simplex virus: receptors and ligands for cell entry.

Patricia G Spear1.   

Abstract

Entry of herpes simplex virus (HSV) into cells depends upon multiple cell surface receptors and multiple proteins on the surface of the virion. The cell surface receptors include heparan sulphate chains on cell surface proteoglycans, a member of the tumor necrosis factor (TNF) receptor family and two members of the immunoglobulin superfamily related to the poliovirus receptor. The HSV ligands for these receptors are the envelope glycoproteins gB and gC for heparan sulphate and gD for the protein receptors and specific sites in heparan sulphate generated by certain 3-O-sulfotransferases. HSV gC also binds to the C3b component of complement and can block complement-mediated neutralization of virus. The purposes of this review are to summarize available information about these cell surface receptors and the viral ligands, gC and gD, and to discuss roles of these viral glycoproteins in immune evasion and cellular responses as well as in viral entry.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056211     DOI: 10.1111/j.1462-5822.2004.00389.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  250 in total

1.  Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

Authors:  Hyunjung Baek; Hiroaki Uchida; Kyungok Jun; Jae-Hong Kim; Masahide Kuroki; Justus B Cohen; Joseph C Glorioso; Heechung Kwon
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion.

Authors:  Na Zhang; Jinghua Yan; Guangwen Lu; Zhengfei Guo; Zheng Fan; Jiawei Wang; Yi Shi; Jianxun Qi; George F Gao
Journal:  Nat Commun       Date:  2011-12-06       Impact factor: 14.919

3.  Glycoprotein B of herpes simplex virus 2 has more than one intracellular conformation and is altered by low pH.

Authors:  Martin I Muggeridge
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

4.  Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL.

Authors:  Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

5.  Role of nectin-1, HVEM, and PILR-alpha in HSV-2 entry into human retinal pigment epithelial cells.

Authors:  Shripaad Y Shukla; Yogesh K Singh; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

6.  Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is dependent on entry receptor expression and route of inoculation.

Authors:  Sarah J Kopp; Andrew H Karaba; Laura K Cohen; Ghazal Banisadr; Richard J Miller; William J Muller
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

Review 7.  Herpesvirus Evasion of Natural Killer Cells.

Authors:  Steffi De Pelsmaeker; Nicolas Romero; Massimo Vitale; Herman W Favoreel
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

8.  Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry.

Authors:  Christopher D O'Donnell; Maria Kovacs; Jihan Akhtar; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Virology       Date:  2009-12-11       Impact factor: 3.616

9.  Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1.

Authors:  Ronald Copeland; Arun Balasubramaniam; Vaibhav Tiwari; Fuming Zhang; Arlene Bridges; Robert J Linhardt; Deepak Shukla; Jian Liu
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

10.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.